<!DOCTYPE html><html class="" data-reactroot=""><head><meta charSet="utf-8"/><meta name="save" content="history"/><meta http-equiv="X-UA-Compatible" content="IE=edge"/><meta name="baidu-site-verification" content="VWGb6TyYx8"/><meta content="CAR-T疗法 - 搜狗科学百科" name="keywords"/><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"/><meta http-equiv="x-dns-prefetch-control" content="on"/><meta name="server" baike="235" ip="210" env="online"/><link rel="dns-prefetch" href="//cache.soso.com"/><link rel="dns-prefetch" href="//hhy.sogoucdn.com"/><link rel="dns-prefetch" href="//pic.baike.soso.com"/><link rel="dns-prefetch" href="//ugc.qpic.cn"/><link rel="dns-prefetch" href="//xui.ptlogin2.qq.com"/><link rel="dns-prefetch" href="//q1.qlogo.cn"/><link rel="dns-prefetch" href="//q2.qlogo.cn"/><link rel="dns-prefetch" href="//q3.qlogo.cn"/><link rel="dns-prefetch" href="//q4.qlogo.cn"/><link rel="dns-prefetch" href="//q.qlogo.cn"/><link rel="dns-prefetch" href="//img01.sogoucdn.com"/><link rel="dns-prefetch" href="//img02.sogoucdn.com"/><link rel="dns-prefetch" href="//img03.sogoucdn.com"/><link rel="dns-prefetch" href="//img04.sogoucdn.com"/><link rel="Shortcut Icon" href="//www.sogou.com/images/logo/new/favicon.ico?v=4"/><link rel="Bookmark" href="//www.sogou.com/images/logo/new/favicon.ico?v=4"/><link href="//hhy.sogoucdn.com/deploy/ued/new_baike/pc/dist/css/base_b849887.css" rel="stylesheet"/><link href="//hhy.sogoucdn.com/deploy/ued/new_baike/pc/dist/css/detail/detail_378aed5.css" rel="stylesheet"/><link href="//hhy.sogoucdn.com/deploy/ued/new_baike/pc/dist/css/inviteAudit/inviteAudit_7894507.css" rel="stylesheet"/><link rel="stylesheet" href="//hhy.sogoucdn.com/js/lib/highlight/highlight.min.css"/><title>CAR-T疗法 - 搜狗科学百科</title></head><body><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('666c28efe6024632894c4af2f1db3317') window._gtag.traceId = '666c28efe6024632894c4af2f1db3317';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="//www.sogou.com/web?query=">网页</a></li><li><a href="//weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="//zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="//pic.sogou.com/pics?query=">图片</a></li><li><a href="//v.sogou.com/v?query=">视频</a></li><li><a href="//mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="//hanyu.sogou.com/">汉语</a></li><li><a href="//wenwen.sogou.com/">问问</a></li><li><a href="//www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header"><div class="header-wrap"><a class="header-logo" href="/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>CAR-T疗法</h1><a href="#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="48758967727332865"><div class="text_img ed_imgfloat_right"><a class="ed_image_link" data-src="https://img01.sogoucdn.com/app/a/200698/480_360_20200802164853-623130268.jpg" data-bigsrc="https://img01.sogoucdn.com/app/a/200698/480_360_20200802164853-623130268.jpg?width=227&amp;height=174&amp;titlename=CAR-T%E7%96%97%E6%B3%95%E8%BF%87%E7%A8%8B&amp;w=480&amp;h=360" title="点击查看大图" data-w="480" data-h="360" style="background-image:url(https://img01.sogoucdn.com/app/a/200698/480_360_20200802164853-623130268.jpg)" href="#!"></a><div class="text_img_title">CAR-T疗法过程</div></div><div><p>ＣＡＲ⁃Ｔ 疗法全称为 chimeric antigen recptor T-cell therapy，即嵌合抗原受体Ｔ细胞免疫疗<span>法。</span><span>CAR-T(嵌合抗原受体T细胞)是通过基因改造技术，让患者T细胞表达嵌合抗原受体，使效应T细胞的靶向性、杀伤性和持久性均较常规应用的免疫细胞高，并能克服肿瘤局部免疫抑制微环境和打破宿主免疫耐受状态。</span></p></div></div><div id="catalog"></div><div id="paragraphs"></div><div id="references"></div><div class="read-num">阅读 <!-- -->246</div></div><div class="right-side" id="rightSide"></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"48750671377243909","versionId":"48758967710555658","title":"CAR-T疗法","subtitle":"","abstracts":{"paragraphId":"48758967727332865","title":"摘要","versionId":"48758967710555659","lemmaId":48750671377243910,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81101212,"name":"_will_3","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1596358609,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p>ＣＡＲ⁃Ｔ 疗法全称为 chimeric antigen recptor T-cell therapy，即嵌合抗原受体Ｔ细胞免疫疗<span>法。</span><span>CAR-T(嵌合抗原受体T细胞)是通过基因改造技术，让患者T细胞表达嵌合抗原受体，使效应T细胞的靶向性、杀伤性和持久性均较常规应用的免疫细胞高，并能克服肿瘤局部免疫抑制微环境和打破宿主免疫耐受状态。</span></p>","pics":[{"originalUrl":"https://img01.sogoucdn.com/app/a/200698/480_360_20200802164853-623130268.jpg?width=227&height=174&titlename=CAR-T%E7%96%97%E6%B3%95%E8%BF%87%E7%A8%8B&w=480&h=360","url":"https://img01.sogoucdn.com/app/a/200698/480_360_20200802164853-623130268.jpg","rw":480,"rh":360,"title":"CAR-T疗法过程","alt":null,"width":227,"height":174}],"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"48758967710555670","title":"基本信息","versionId":"48758967710555660","lemmaId":48750671377243910,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81101212,"name":"_will_3","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1596358609,"comment":null,"dependVersionId":0,"contentType":3,"content":"","pics":null,"card":{"cardItems":[{"key":"中文名称","value":"嵌合抗原受体T细胞疗法"},{"key":"英文","value":"Chimeric Antigen Receptor T-Cell Therapy"},{"key":"提出者","value":"GRoss"},{"key":"提出时间","value":"1989年"},{"key":"所属领域","value":"细胞学"}]},"references":[],"versionCount":0},"categories":[{"id":162,"name":"细胞免疫学","parents":[[{"id":4,"name":"生物学","parents":null},{"id":157,"name":"细胞生物学","parents":null}]]}],"creator":{"uid":81101212,"name":"杨燕","pic":"https://cache.soso.com/wenwen/i/default-thumb.png","introduction":null,"educations":[{"schoolName":"上海交通大学","major":"","degree":"硕士","universityId":30,"universityLogo":"https://img01.sogoucdn.com/app/a/200943/b631e6dc-6011-11e9-a530-fc4dd4f70029","majorLevel1":"理学","majorLevel2":"药学","majorLevel3":"生药学","majorLevel1Id":1,"majorLevel2Id":342,"majorLevel3Id":344,"state":"在读","lab":"中药基因组学","researchField":""}],"jobs":null,"works":null,"educationBrief":"上海交通大学","jobBrief":"","role":0,"roleName":null,"title":"上海交通大学 · 药学硕士","professionalTitle":"学生","phoneNo":null,"editable":true,"partnerId":218,"partnerIdCreateTime":1595845061,"partnerIdPoped":true},"createTime":1596353664,"editor":{"uid":81101212,"name":"杨燕","pic":"https://cache.soso.com/wenwen/i/default-thumb.png","introduction":null,"educations":[{"schoolName":"上海交通大学","major":"","degree":"硕士","universityId":30,"universityLogo":"https://img01.sogoucdn.com/app/a/200943/b631e6dc-6011-11e9-a530-fc4dd4f70029","majorLevel1":"理学","majorLevel2":"药学","majorLevel3":"生药学","majorLevel1Id":1,"majorLevel2Id":342,"majorLevel3Id":344,"state":"在读","lab":"中药基因组学","researchField":""}],"jobs":null,"works":null,"educationBrief":"上海交通大学","jobBrief":"","role":0,"roleName":null,"title":"上海交通大学 · 药学硕士","professionalTitle":"学生","phoneNo":null,"editable":true,"partnerId":218,"partnerIdCreateTime":1595845061,"partnerIdPoped":true},"editTime":1596358609,"state":1,"versionCount":1,"upNum":1,"downNum":0,"pics":[{"originalUrl":"https://img01.sogoucdn.com/app/a/200698/480_360_20200802164853-623130268.jpg?width=227&height=174&titlename=CAR-T%E7%96%97%E6%B3%95%E8%BF%87%E7%A8%8B&w=480&h=360","url":"https://img01.sogoucdn.com/app/a/200698/480_360_20200802164853-623130268.jpg","rw":480,"rh":360,"title":"CAR-T疗法过程","alt":null,"width":227,"height":174},{"originalUrl":"https://img03.sogoucdn.com/app/a/200698/500_315_20200802165020-588555614.jpg?w=500&h=315&titlename=%E5%B5%8C%E5%90%88%E6%8A%97%E5%85%83%E5%8F%97%E4%BD%93","url":"https://img03.sogoucdn.com/app/a/200698/500_315_20200802165020-588555614.jpg","rw":500,"rh":315,"title":"嵌合抗元受体","alt":null,"width":0,"height":0},{"originalUrl":"https://img04.sogoucdn.com/app/a/200698/600_300_20200802165323-1492673362.jpg?w=600&h=300&titlename=%E5%8D%95%E9%93%BE%E6%8A%97%E4%BD%93%EF%BC%88scFv%EF%BC%89","url":"https://img04.sogoucdn.com/app/a/200698/600_300_20200802165323-1492673362.jpg","rw":600,"rh":300,"title":"单链抗体（scFv）","alt":null,"width":0,"height":0},{"originalUrl":"https://img04.sogoucdn.com/app/a/200698/632_430_20200802163640-679919713.png?w=632&h=430&titlename=CAR-T%E6%B2%BB%E7%96%97%E8%BF%87%E7%A8%8B","url":"https://img04.sogoucdn.com/app/a/200698/632_430_20200802163640-679919713.png","rw":632,"rh":430,"title":"CAR-T治疗过程","alt":null,"width":0,"height":0},{"originalUrl":"https://img03.sogoucdn.com/app/a/200698/501_333_20200802165454-324510830.jpg?w=501&h=333&titlename=Emily%20Whitehead","url":"https://img03.sogoucdn.com/app/a/200698/501_333_20200802165454-324510830.jpg","rw":501,"rh":333,"title":"Emily Whitehead","alt":null,"width":0,"height":0}],"catalogs":[{"level":1,"title":"简介","paragraphId":"48758967727332867","subCatalogs":null},{"level":1,"title":"CＡＲ⁃Ｔ的整体结构与功能","paragraphId":"48758967710555669","subCatalogs":null},{"level":1,"title":"CAR-T的发展","paragraphId":"48758967710555668","subCatalogs":null},{"level":1,"title":"CAR-T的结构组分研究","paragraphId":"48758967727332866","subCatalogs":[{"level":2,"title":"scFV研究","paragraphId":"48758967727332866","subCatalogs":null},{"level":2,"title":"载体设计研究","paragraphId":"48758967727332866","subCatalogs":null},{"level":2,"title":"效应细胞设计","paragraphId":"48758967727332866","subCatalogs":null}]},{"level":1,"title":"CAR-T细胞治疗流程","paragraphId":"48758967710555671","subCatalogs":null},{"level":1,"title":"CAR-T疗法的诞生","paragraphId":"48758967727332868","subCatalogs":null},{"level":1,"title":"CAR-T的副作用","paragraphId":"48758967744110080","subCatalogs":null},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"48758967727332867","title":"简介","versionId":"48758967710555661","lemmaId":48750671377243910,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81101212,"name":"_will_3","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1596358609,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>&nbsp; &nbsp; &nbsp; <img class=\"kx_img ed_imgfloat_right\" width=\"227\" height=\"174\" titlename=\"嵌合抗元受体\" bigsrc=\"https://img03.sogoucdn.com/app/a/200698/500_315_20200802165020-588555614.jpg\" data-src=\"https://img03.sogoucdn.com/app/a/200698/500_315_20200802165020-588555614.jpg\">嵌合抗原受体(CARs)是由一个胞外抗原结合域(通常是一个单链抗体，也可以是多肽或者其他蛋白质)，一个铰链区(促进抗原受体与肿瘤抗原的结合)，一个跨膜区(用来固定CAR)，一个T细胞激活结构域(CD3 ζ，提供T细胞活化的第一信号)以及一个或多个胞内共刺激结构域组成(CD28/4-1BB，提供T细胞活化的第二信号)。CAR的胞外部分用来识别特异性的肿瘤抗原，随后胞内信号域会刺激T细胞增殖，并且通过细胞溶解和细胞因子释放来消除肿瘤细胞。</p><p>&nbsp; &nbsp; &nbsp; &nbsp;CAR-T，是Chimeric Antigen Receptor T-Cell Therapy（嵌合抗原受体T细胞疗法）的简称，&nbsp;这一概念最早由Gross<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> 等于 1989年提出，经过近几年连续改进并发展后得到了非常快速的进步。是一种比较新式的肿瘤免疫疗法。它把病人自身免疫系统的T细胞提取出来，经过体外培养和改造，给这些T细胞装备上特殊分子，使它们能识别并攻击特定的癌细胞，再把改造过后的T细胞注射回病人身体，由这些T细胞针对癌细胞的免疫反应来消灭癌细胞。</p><p>&nbsp; &nbsp; &nbsp; &nbsp;CAR-T疗法的关键之一，就是要给T细胞装备能识别特定癌细胞的分子，就像装备特殊的探测器。被改造以后的T细胞就成为CAR-T细胞，它们在身体内四处游走，一旦探测器接收到来自别的细胞表面的特异信号，就会激活CAR-T细胞，发动攻击，把带信号的细胞当作敌人消灭掉。</p>","pics":[{"originalUrl":"https://img03.sogoucdn.com/app/a/200698/500_315_20200802165020-588555614.jpg?w=500&h=315&titlename=%E5%B5%8C%E5%90%88%E6%8A%97%E5%85%83%E5%8F%97%E4%BD%93","url":"https://img03.sogoucdn.com/app/a/200698/500_315_20200802165020-588555614.jpg","rw":500,"rh":315,"title":"嵌合抗元受体","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"48758967710555669","title":"CＡＲ⁃Ｔ的整体结构与功能","versionId":"48758967710555662","lemmaId":48750671377243910,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81101212,"name":"_will_3","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1596358609,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>&nbsp; &nbsp; &nbsp; 经典的嵌合型抗原受体CAR可分为 ５ 个部分，即识别肿瘤抗原的抗体单链可变区、铰链区、跨膜区、共刺激区和T细胞活化区。 CAR-T 细胞技术通过外源基因转染技术转染到患者的T细胞或者改造的T细胞，把识别肿瘤相关抗原（ tumor-associated antigen,TAA) 的单链抗体（ single-chain variable fragment,scFV)和T细胞活化序列（通常为 ＣD３ζ 或 FｃεＲＩγ） 的融合蛋白表达到T细胞表面。 scFV 通过跨膜区与T细胞胞内的活化增殖信号域偶联。 这些改造的T细胞再经过体外纯化和大规模扩增后回输到患者体内，最终以非主要组织相容性复合体（ major histocompatibility complex ,MHC)限制性模式表现强效的抗癌作用。CAR-T 细胞作用过程不受MHC限制，这在一定程度上使得 CAR-T 细胞技术具有多靶点性，而且对表达相同抗原的肿瘤均具有识别杀伤能力。 迄今，CAR-T细胞技术主要经历了4代研发历程，但有研究提出第Ⅴ 代应为通用型嵌合抗原受体。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"48758967710555668","title":"CAR-T的发展","versionId":"48758967710555663","lemmaId":48750671377243910,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81101212,"name":"_will_3","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1596358609,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>&nbsp; &nbsp; &nbsp;1989年，第一代基于免疫球蛋白样scFv和FcεRI受体(γ链)或CD3复合物(ζ链)胞内结构域融合的Car-T细胞被发展出来。该CAR-T细胞虽然具有激活T细胞的能力，但是只含有激活受体CD3-ζ，无法完全激活其活性。大多数试验在细胞扩增、体内存活时间、细胞因子分泌等方面存在不足，治疗效果不明显。</p><p>&nbsp; &nbsp; &nbsp;2010年，在第一代的基础上，第二代CAR引入一个共刺激受体结构域(包括CD28、4-1BB、DAP10等)，CD28对提高初始T细胞获得持久的体外增殖和较强的细胞因子分泌非常重要，在临床试验中显着改善了CAR-T免疫活性激活的问题，并提高了其作用持久性。</p><p>&nbsp; &nbsp; &nbsp; 2012年，以逆转录病毒为载体构建了第三代CAR-T细胞，第三代CAR则包含两个共刺激结构域，一个为CD28或4-1BB，另一个为OX40、CD28或4-1BB。相比于二代CAR，虽然在一些前临床试验数据中表现出更强更持久的作用活性，但也有报道指出，三代CAR可能会造成T细胞刺激阈值的降低，引起信号泄露，可能诱发细胞因子过量释放。</p><p>&nbsp; &nbsp; &nbsp; 第四代Car-T细胞，在保留了第三代两个共刺激和激活信号的基础上，还进一步引入了分泌细胞因子(主要是IL-12)的基因，被称为TRUCK T细胞(T cell redirected for universal cytokine-mediated killing)。TRUCKs还可以用于病毒感染、代谢病与自身免疫病等领域。</p><p>&nbsp; &nbsp; &nbsp;然而，对目前来说，第三、四代Car-T细胞发展仍未完善，仍有诸多问题有待解决，第二代Car-T细胞对于血液恶性肿瘤具有很好的疗效，是Car-T领域的主流。</p><table><tbody><tr><td width=\"253\">CAR-T代数<br></td><td width=\"253\">CAR-T因子修饰<br></td><td width=\"253\">效用<br></td></tr><tr><td width=\"253\">第一代<br></td><td width=\"253\">CD3ζ</td><td width=\"253\">体外T细胞激活，具有常规T细胞杀伤毒性，但在体内无法增殖与长期存活</td></tr><tr><td width=\"253\">第二代</td><td width=\"253\">cd3ζ+CD28/CD134/CD137</td><td width=\"253\">加入一个共刺激分子，体内存活时间延长，增殖能力、杀伤毒性提高</td></tr><tr><td width=\"253\">第三代</td><td width=\"253\">CD3ζ+CD28/CD134/CD137+CD28/CD134/CD137</td><td width=\"253\">加入2个不同的共刺激分子，增殖能力、杀伤毒性进一步提高</td></tr><tr><td width=\"253\">第四代</td><td width=\"253\">自杀基因/CAR-T(IL-12)/PD-1敲除等</td><td width=\"253\">自杀基因编辑、免疫因子改造等各种整合性、精细化调控手段</td></tr><tr><td colspan=\"1\" rowspan=\"1\">第五代</td><td colspan=\"1\" rowspan=\"1\">通用CAR-T,基因编辑</td><td colspan=\"1\" rowspan=\"1\">无个体限制，规模化生产与治疗</td></tr></tbody></table>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"48758967727332866","title":"CAR-T的结构组分研究","versionId":"48758967710555664","lemmaId":48750671377243910,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81101212,"name":"_will_3","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1596358609,"comment":null,"dependVersionId":0,"contentType":1,"content":"<h3>scFV研究</h3><p>&nbsp; &nbsp; <img class=\"kx_img ed_imgfloat_right\" width=\"227\" height=\"174\" titlename=\"单链抗体（scFv）\" bigsrc=\"https://img04.sogoucdn.com/app/a/200698/600_300_20200802165323-1492673362.jpg\" data-src=\"https://img04.sogoucdn.com/app/a/200698/600_300_20200802165323-1492673362.jpg\">嵌合型抗原受体CAR结构的第一个关键部位是膜外区上具有特异性识别并结合肿瘤细胞表面抗原的scFv,其形式为VH-Linker-VL或VL-Linker-VH。目前能获得的最小的具有特异性识别又能结合抗原的分子为scFv<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup>,其大小约为28KD。scFv既可以与纳米微球结合，也可以与各种已知的靶向治疗药物结合。对靶标分子及修饰性目的分子的亲和淘选是目前获得较特异的scFv片段分子的有效方式。 其中，较为常用的筛选方法包括DNA文库、噬菌体文库、核糖体展示文库等筛选文库技术。&nbsp;</p><p>&nbsp; &nbsp;scFv亲和淘选及识别靶点既可以利用肿瘤蛋白质抗原，又可利用糖脂类非蛋白质、碳水化合物或肿瘤特异性受体的配体等。目前世界范围内多个中心研究较多的靶点为特定或某一类肿瘤相关抗原，而实体瘤的靶向选择主要包括突变的抗原或病毒抗原、组织特异性抗原、组织发育特异性抗原、过表达的抗原等<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup> 。</p><h3>载体设计研究</h3><p>&nbsp; &nbsp; &nbsp; 目前应用最多的CAR-T细胞技术仍是以病毒作为载体中介,其中最为常见的仍是反转录病毒和慢病毒。两者均具有出色的基因转导效率，而慢病毒的感染效率更高，表达更持久且能传递大片段DNA序列。人们对其他病毒也有研究，如Pule等<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup>报道了尝试使用EB病毒转化第一代CAR-T细胞，取得了一定的疗效。溶瘤病毒（oncolytic virus,OV)作为载体的研究目前已取得了可喜的进展，这得益于溶瘤病毒能选择性感染肿瘤细胞，并在其中复制且杀伤肿瘤细胞，但不会伤及健康组织。</p><p>&nbsp; &nbsp; &nbsp; 改造的T细胞装载OV可能是一种能提高疗效的新的联合疗法。就病毒载体的安全性而言，研究<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup>表明在小鼠和人T细胞中，CAR-T细胞负载低剂量病毒不会影响受体的表达和功能,但仍需更长时间观察病毒载体是否会带来有害的插入性突变。</p><p>&nbsp; &nbsp; &nbsp;与病毒载体相比，质粒载体的构建花费较少，而且不会整合到宿主的基因组中，安全性有一定保证。但是，质粒载体的构建需要花费更多时间，如需要一个长期的体外培养和抗性筛选过程，人类对质粒载体的抗性基因的免疫反应等限制了其临床应用研究。在物理呈递和化学诱导方面，电穿孔技术适用性较广，安全性较高，但效率较低的缺点较明显。分子技术层面转染CAR-T细胞进展很快，如为体外转录编码CAR的mRNA,微环DNA等都作为转导载体进行研究。</p><h3>效应细胞设计</h3><p>&nbsp; &nbsp; Ｔ细胞可来源于自体或者是健康异体，如果采用志愿者的T细胞，需要克服异体排斥反应。可利用基因编辑改造在CAR-T细胞。一般回输T细胞前，需要对患者进行预处理，主要是通过调节化疗延长过继 Ｔ 细胞的存在</p><p>时间。 基于安全性考虑，凯特琳癌症研究中心将T细胞过继调整为化疗后 ２ 天；而美国国家癌症研究所认为低剂量化疗联合CAR-T疗法对进展性B细胞淋巴瘤效果较好。目前，重组T细胞的回输方式主要是静脉回输，采用腹膜或瘤体注射的研究大部分还处在试验阶段，而采用微创介入或瘤内注射的方式可使CAR-T细胞更多地进入实体瘤内部对靶细胞进行有效杀伤，可能是未来CAR-T治疗实体瘤的方向之一。</p>","pics":[{"originalUrl":"https://img04.sogoucdn.com/app/a/200698/600_300_20200802165323-1492673362.jpg?w=600&h=300&titlename=%E5%8D%95%E9%93%BE%E6%8A%97%E4%BD%93%EF%BC%88scFv%EF%BC%89","url":"https://img04.sogoucdn.com/app/a/200698/600_300_20200802165323-1492673362.jpg","rw":600,"rh":300,"title":"单链抗体（scFv）","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"48758967710555671","title":"CAR-T细胞治疗流程","versionId":"48758967710555665","lemmaId":48750671377243910,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81101212,"name":"_will_3","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1596358609,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><img class=\"kx_img ed_imgfloat_right\" width=\"227\" height=\"174\" titlename=\"CAR-T治疗过程\" bigsrc=\"https://img04.sogoucdn.com/app/a/200698/632_430_20200802163640-679919713.png\" data-src=\"https://img04.sogoucdn.com/app/a/200698/632_430_20200802163640-679919713.png\">第一步：T细胞收集、分离、活化，T细胞离开人体后需要合适的培养环境才能存活，因此，选择合适的培养基是开展CAR-T研究的开端。T细胞体外活化最常用的是CD3抗体和CD28抗体。CD3单克隆抗体（OKT3）能够特异性识别T细胞表面的CD3分子，通过T细胞表面TCR-CD3复合物与抗原提呈细胞表面MHC-II类分子-抗原肽的结合，导致T细胞活化、增殖。激动型CD28抗体对天然CD28受体的伴随刺激可以进一步促进T细胞的活化。</p><p>第二步：筛选肿瘤相关靶点蛋白，肿瘤相关靶点可以说是CAR-T疗法的“灵魂”所在。不同的肿瘤会造成不同的基因突变，表达的蛋白也会不同。经过科学家不懈的努力，不断有新的肿瘤相关靶点被发现。</p><p>第三步：CAR-T细胞基因转导，CAR-T细胞基因转导常见的方法有慢病毒载体、逆转录病毒载体、转座子和mRNA电穿孔技术是较为常见转导方法。</p><p>第四步：CAR-T细胞体外增殖培养，通过基因技术改造的CAR-T细胞需要在体外培养到一定的数量才能达到治疗要求，回输到患者体内。一般一个病人需要几十亿到上百亿个CAR-T细胞。CAR-T细胞的健康生长离不开相关细胞因子。细胞因子（CKs）是一类具有广泛生物学活性的小分子蛋白质（约 5 -20kDa），它们在细胞培养过程中发挥重要作用。</p><p>第五步：CAR-T细胞质量检测，CAR-T细胞回输到患者体内前需经过严格的放行检测。CAR-T细胞的质量检测主要包括生化检测、微生物检测和细胞学检测。生化检测主要用于 CAR-T的鉴别和纯度检测；细胞学检测主要是细胞计数、活率检测、体外效价检测（ELISA 检测试剂盒）等；微生物检测主要进行总厌氧菌计数、酵母和霉菌检测等。CAR-T细胞质量的优劣直接影响临床治疗效果和患者的健康，如不进行严格检测，甚至会危及患者的生命。</p>","pics":[{"originalUrl":"https://img04.sogoucdn.com/app/a/200698/632_430_20200802163640-679919713.png?w=632&h=430&titlename=CAR-T%E6%B2%BB%E7%96%97%E8%BF%87%E7%A8%8B","url":"https://img04.sogoucdn.com/app/a/200698/632_430_20200802163640-679919713.png","rw":632,"rh":430,"title":"CAR-T治疗过程","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"48758967727332868","title":"CAR-T疗法的诞生","versionId":"48758967710555666","lemmaId":48750671377243910,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81101212,"name":"_will_3","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1596358609,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>&nbsp; &nbsp; <img class=\"kx_img ed_imgfloat_right\" width=\"227\" height=\"174\" titlename=\"Emily Whitehead\" bigsrc=\"https://img03.sogoucdn.com/app/a/200698/501_333_20200802165454-324510830.jpg\" data-src=\"https://img03.sogoucdn.com/app/a/200698/501_333_20200802165454-324510830.jpg\">CAR-T疗法的诞生，很大程度上要归功于Michel Sadelain医生等人从上世纪九十年代早期就开始潜心研究怎样改造T细胞、让它们攻击癌细胞。而CAR-T疗法后来能成功走向临床应用、并走入大众视野，则与费城儿童医院的Carl June医生用CAR-T试验疗法成功治疗了Emily Whitehead小姑娘的故事分不开的。</p><p>&nbsp; &nbsp; 一名叫Emily Whitehead的小姑娘在五岁时不幸患上急性B淋巴细胞白血病（B-ALL）。B-ALL是一种在儿童中最常见的白血病，治愈率高达85-90%，但是那另外10-15%的难治、易复发患者的病情就比较棘手，存活率很低。而Emily小姑娘患上的B-ALL，就是难治的这一种，在经过化疗、骨髓移植以后仍然复发，到了无药可救的阶段。当时费城医院刚启动CAR-T疗法的临床试验，Emily幸运地成为了第一个接受这种疗法的儿童。</p><p>Emily的T细胞被改造之后，回到她的体内，非常积极地清除癌细胞，在它们努力消灭白血病过程中释放出的大量细胞因子，一度到了令Emily的身体无法承受的程度。这是医疗团队事先完全无法预料的危险状况，险些令人措手不及。而巧合的是，Carl June医生的女儿因为患有类风湿关节炎，正在接受抑制同一种细胞因子的治疗，这让Carl June能够迅速地做出判断，争分夺秒地找到有效药，控制住了Emily的细胞因子风暴，救了Emily的命，也救了CAR-T——Emily从细胞因子风暴中活了下来，CAR-T疗法旗开得胜，治好了她的白血病。随着Emily的例子被媒体广泛报道，CAR-T疗法也走到聚光灯下。</p>","pics":[{"originalUrl":"https://img03.sogoucdn.com/app/a/200698/501_333_20200802165454-324510830.jpg?w=501&h=333&titlename=Emily%20Whitehead","url":"https://img03.sogoucdn.com/app/a/200698/501_333_20200802165454-324510830.jpg","rw":501,"rh":333,"title":"Emily Whitehead","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"48758967744110080","title":"CAR-T的副作用","versionId":"48758967710555667","lemmaId":48750671377243910,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81101212,"name":"_will_3","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1596358609,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>&nbsp; &nbsp; CAR-T治疗中最主要的副作用就是细胞因子风暴(cytokine release syndrome, CRS)，也是CAR-T技术在临床应用中一个最主要的不良反应。由于T细胞在体内的大量增殖，导致细胞因子释放出来，引起患者出现发热或发烧，肌痛，低血压，呼吸衰竭等症状，这是导致试验患者死亡的主要原因之一。</p><p>&nbsp; &nbsp; &nbsp;还有一个副作用是靶向非肿瘤细胞毒性。由于CAR-T抗原的靶向性非常强，无法区分表达相应抗原的肿瘤细胞和正常细胞，因此CAR-T都会攻击表达相应抗原的肿瘤细胞和正常细胞。比如，针对CD19的CAR-T细胞治疗，导致B细胞发育不良，靶向HER2的CAR-T细胞会导致其他组织或器官遭受攻击，如心肺系统毒性。</p><p>&nbsp; &nbsp; 来自北京大学肿瘤医院的朱军教授团队和南加州大学Si-Yi Chen教授团队合作在Nature Medicine上发表了最新研究<sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup>，表明他们的新方法可以消除CAR-T疗法的严重副作用，使得这种疗法更加安全。研究人员调整了CAR的序列和形状，使得这些CAR-T细胞可以杀伤癌细胞，但是产生的细胞因子更少，增殖速度更慢，因此血液有足够的时间清除细胞因子。这个改进版的CAR-T细胞可以在病人体内增殖并分化为记忆细胞，因此会产生强烈而持久的抗癌效应，同时不会引起毒副作用。</p>","pics":null,"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"journal","title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.","site":"","url":"http://www.pnas.org/cgi/doi/10.1073/pnas.86.24.10024","journalName":"Proceedings of the National Academy of Sciences","author":"G. Gross,T. Waks,Z. Eshhar","press":"","publishYear":"","publishTime":"1989-12-01","publishPlace":"","page":"10024-10028","volume":"86","quoteTime":"2020-08-02","quoted":false},{"id":2,"type":"journal","title":"An engineered anti-CA19-9 cys-diabody for PET imaging of pancreas cancer and targeting of polymerized liposomal nanoparticles.","site":"","url":"http://ascopubs.org/doi/10.1200/jco.2011.29.4_suppl.198","journalName":"Journal of Clinical Oncology","author":"M. D. Girgis,K. McCabe,T. Olafsen,F. Bergara,V. Kenanova,N. Federman,A. Wu,J. S. Tomlinson","press":"","publishYear":"","publishTime":"2011-02-01","publishPlace":"","page":"198-198","volume":"29","quoteTime":"2020-08-02","quoted":false},{"id":3,"type":"journal","title":"Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy","site":"","url":"https://linkinghub.elsevier.com/retrieve/pii/S0952791510002141","journalName":"Current Opinion in Immunology","author":"Cameron J Turtle,Stanley R Riddell","press":"","publishYear":"","publishTime":"2011-04","publishPlace":"","page":"299-305","volume":"23","quoteTime":"2020-08-02","quoted":false},{"id":4,"type":"journal","title":"71: Virus-specific T cells engineered to co-express tumor-specific receptors; effects in patients with neuroblastoma","site":"","url":"https://linkinghub.elsevier.com/retrieve/pii/S1083879106009268","journalName":"Biology of Blood and Marrow Transplantation","author":"G.D. Myers,M.A. Pule,H. Russell,E. Liu,H.L. Weiss,G. Dotti,T. Lopez,C.M. Rooney,H.E. Heslop,M.K. Brenner","press":"","publishYear":"","publishTime":"2007-02","publishPlace":"","page":"29","volume":"13","quoteTime":"2020-08-02","quoted":false},{"id":5,"type":"journal","title":"Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells","site":"","url":"https://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.3003761","journalName":"Science Translational Medicine","author":"J. Scholler,T. L. Brady,G. Binder-Scholl,W.-T. Hwang,G. Plesa,K. M. Hege,A. N. Vogel,M. Kalos,J. L. Riley,S. G. Deeks,R. T. Mitsuyasu,W. B. Bernstein,N. E. Aronson,B. L. Levine,F. D. Bushman,C. H. June","press":"","publishYear":"","publishTime":"2012-05-02","publishPlace":"","page":"132ra53-132ra53","volume":"4","quoteTime":"2020-08-02","quoted":false},{"id":6,"type":"journal","title":"A safe and potent anti-CD19 CAR T cell therapy","site":"","url":"http://www.nature.com/articles/s41591-019-0421-7","journalName":"Nature Medicine","author":"Zhitao Ying,Xue F. Huang,Xiaoyu Xiang,Yanling Liu,Xi Kang,Yuqin Song,Xiaokai Guo,Hanzhi Liu,Ning Ding,Tingting Zhang,Panpan Duan,Yufu Lin,Wen Zheng,Xiaopei Wang,Ningjing Lin,Meifeng Tu,Yan Xie,Chen Zhang,Weiping Liu,Lijuan Deng,Shunyu Gao,Lingyan Ping,Xuejuan Wang,Nina Zhou,Junqing Zhang,Yulong Wang,Songfeng Lin,Mierzhati Mamuti,Xueyun Yu,Lizhu Fang,Shuai Wang,Haifeng Song,Guan Wang,Lindsey Jones,Jun Zhu,Si-Yi Chen","press":"","publishYear":"","publishTime":"2019-06","publishPlace":"","page":"947-953","volume":"25","quoteTime":"2020-08-02","quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":246,"auditType":1,"synonyms":null,"showEditTime":"2020.08.02 16:56","auditors":[{"uid":77532282,"name":"胡天楠","pic":"https://cache.soso.com/thirdwx_qlogo/mmopen/vi_32/Q0j4TwGTfTLlveSnKicrOD8ABGuGOT9lFkMd2wGmfl9v8GXuuCVCL5icB4IXMskU1xtQ1YDP2Yv5orkDQCZicYTIA/132","introduction":"","educations":[{"schoolName":"加州大学戴维斯分校","major":"","degree":"博士","universityId":114,"universityLogo":"","majorLevel1":null,"majorLevel2":null,"majorLevel3":null,"majorLevel1Id":0,"majorLevel2Id":0,"majorLevel3Id":0,"state":"毕业","lab":"","researchField":""}],"jobs":[{"company":"加州大学旧金山分校","title":"Assistant Specialist"}],"works":null,"educationBrief":"加州大学戴维斯分校","jobBrief":"Assistant Specialist","role":0,"roleName":null,"title":"加州大学戴维斯分校 · 博士","professionalTitle":"加州大学旧金山分校助理研究员","phoneNo":null,"editable":true,"partnerId":11,"partnerIdCreateTime":1594286496,"partnerIdPoped":true},{"uid":78092093,"name":"小科","pic":"https://cache.soso.com/qlogo/g?b=oidb&k=JNl8ymKuOWiaqfJSUCQ5cag&s=100&t=1555468845","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":"","phoneNo":null,"editable":true,"partnerId":215,"partnerIdCreateTime":1595845047,"partnerIdPoped":true}],"hasZhishiNav":false,"auditInfos":{"0":[{"versionId":"0","auditTime":1596503032,"auditorId":77532282,"auditUser":{"uid":77532282,"name":"胡天楠","pic":"https://cache.soso.com/thirdwx_qlogo/mmopen/vi_32/Q0j4TwGTfTLlveSnKicrOD8ABGuGOT9lFkMd2wGmfl9v8GXuuCVCL5icB4IXMskU1xtQ1YDP2Yv5orkDQCZicYTIA/132","introduction":"","educations":[{"schoolName":"加州大学戴维斯分校","major":"","degree":"博士","universityId":114,"universityLogo":"","majorLevel1":null,"majorLevel2":null,"majorLevel3":null,"majorLevel1Id":0,"majorLevel2Id":0,"majorLevel3Id":0,"state":"毕业","lab":"","researchField":""}],"jobs":[{"company":"加州大学旧金山分校","title":"Assistant Specialist"}],"works":null,"educationBrief":"加州大学戴维斯分校","jobBrief":"Assistant Specialist","role":0,"roleName":null,"title":"加州大学戴维斯分校 · 博士","professionalTitle":"加州大学旧金山分校助理研究员","phoneNo":null,"editable":true,"partnerId":11,"partnerIdCreateTime":1594286496,"partnerIdPoped":true},"auditReason":null,"auditSuggest":"词条所涉及的内容是目前的一个热门研究领域，对CART的原理也介绍的较为详细。有以下一些建议，希望进一步修改。1. 可以补充CART在肿瘤以外的领域的应用进展，例如在狼疮等自身免疫病方面。2. 注意括号全半角、换行等格式问题。","auditResult":2,"auditAnnotations":[]},{"versionId":"0","auditTime":1596506293,"auditorId":78092093,"auditUser":{"uid":78092093,"name":"小科","pic":"https://cache.soso.com/qlogo/g?b=oidb&k=JNl8ymKuOWiaqfJSUCQ5cag&s=100&t=1555468845","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":"","phoneNo":null,"editable":true,"partnerId":215,"partnerIdCreateTime":1595845047,"partnerIdPoped":true},"auditReason":null,"auditSuggest":"根据评审者建议给予通过，望加以完善。","auditResult":2,"auditAnnotations":[]}]},"isHistory":false};</script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/aegis-sdk/latest/aegis.min.js"></script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/js/common/polyfill/main_2020092401.js"></script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/js/lib/react/17.0.2/react.production.min.js"></script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/js/lib/react/17.0.2/react-dom.production.min.js"></script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/js/lib/jquery/jquery-1.11.1.min.js"></script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/js/common/hhy/main_2022062701.js"></script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/js/deploy/new_baike/pc/general/main_66bbe21.js"></script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/js/lib/react/17.0.2/react.production.min.js"></script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/js/lib/react/17.0.2/react-dom.production.min.js"></script><script crossorigin="anonymous" src="//hhy.sogoucdn.com/js/deploy/new_baike/pc/detail/main_edf0f08.js"></script><div id="popControl"></div></body></html>